Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics

BACKGROUND: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. However, there are limited data in lower-risk populations. The Heart Outcomes P...

Full description

Bibliographic Details
Main Authors: Lonn, E., Bosch, J., Pogue, J., Avezum, A., Chazova, I., Dans, A., Diaz, R., Fodor, G., Held, C., Jansky, P., Keltai, M., Keltai, K., Kunti, K., Kim, J., Leiter, L., Lewis, B., Liu, L., Lopez-Jaramillo, P., Pais, P., Parkhomenko, A., Peters, R., Piegas, L., Reid, Christopher, Sliwa, K., Toff, W., Varigos, J., Xavier, D., Yusoff, K., Zhu, J., Dagenais, G., Yusuf, S., HOPE-3 Investigators
Format: Journal Article
Published: 2015
Online Access:http://hdl.handle.net/20.500.11937/37425